Argatroban Anticoagulation in Patients With Heparin-Induced Thrombocytopenia

Why is this work in the frame?

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Teacher spread

0.256 · how far apart the two teachers sit on this one work

Validation status

score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Abstract

BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an intensely prothrombotic syndrome managed by discontinuation of heparin therapy and substitution of an alternative inhibitor of thrombin. We describe our experience with argatroban, a direct thrombin inhibitor, in patients with HIT or HIT with thrombosis (HITTS). METHODS: In this multicenter, nonrandomized prospective study, 418 patients with HIT were administered intravenous argatroban, 2 micro g/kg per minute, adjusted to maintain the activated partial thromboplastin time at 1.5 to 3 times the baseline value for a mean of 5 to 7 days. Comparisons were made with a historical control cohort (n = 185). The prospectively defined, primary efficacy end point was a composite of all-cause death, all-cause amputation, or new thrombosis in 37 days. Other end points included the components of the composite, death due to thrombosis, increased platelet count, and bleeding. RESULTS: In the HIT arm, the composite end point was significantly reduced in argatroban-treated patients vs controls (28.0% vs 38.8%; P =.04). In the HITTS arm, the composite end point occurred in 41.5% of argatroban-treated patients vs 56.5% of controls (P =.07). By time-to-event analysis of the composite end point, argatroban therapy was significantly better than historical control therapy in HIT (P =.02) and HITTS (P =.008). Argatroban therapy also significantly reduced new thrombosis in HIT and HITTS and death due to thrombosis in HITTS. There were no significant between-group differences in all-cause death or amputation. Platelet counts recovered more rapidly in argatroban-treated patients than in controls. Bleeding rates were similar between groups. CONCLUSION: Argatroban therapy, compared with historical control, improves outcomes, particularly new thrombosis and death due to thrombosis, in patients with heparin-induced thrombocytopenia.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

The record

Venue

Archives of Internal Medicine

Topic

Heparin-Induced Thrombocytopenia and Thrombosis

Field

Medicine

Canadian institutions

—

Funders

Medical Center, University of RochesterClaude Pepper Older Americans Independence Center, Wake Forest School of MedicineUniversity of California, San FranciscoCollege of Engineering, Michigan State UniversityNational Institutes of HealthUniversity of AlbertaUniversity of RochesterBrigham and Women's HospitalCleveland Clinic FoundationMichigan State UniversityCleveland ClinicGeorge Washington UniversityHeart and Stroke Foundation of CanadaNorthwestern UniversityUniversity of Nebraska Medical CenterYale UniversitySchool of Medicine, University of North Carolina at Chapel HillOchsner HealthGlaxoSmithKlineMassachusetts General Hospital

Keywords

ArgatrobanMedicineDirect thrombin inhibitorHeparin-induced thrombocytopeniaThrombosisDiscontinuationDiscovery and development of direct thrombin inhibitorsHeparinInternal medicineSurgeryWarfarinAnesthesiaPlateletThrombinAtrial fibrillation

Has abstract in OpenAlex

yes

API

/api/v1/works/W2126850862